CINECA IRIS Institutional Research Information System

SAINAS, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.245
EU - Europa 2.111
AS - Asia 1.171
AF - Africa 40
SA - Sud America 38
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.618
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.154
IT - Italia 830
CN - Cina 381
SG - Singapore 381
IE - Irlanda 293
SE - Svezia 200
DE - Germania 152
FR - Francia 117
GB - Regno Unito 109
IN - India 103
AT - Austria 92
CA - Canada 79
UA - Ucraina 67
FI - Finlandia 55
VN - Vietnam 52
HK - Hong Kong 50
ID - Indonesia 40
JP - Giappone 38
PL - Polonia 28
BE - Belgio 27
KR - Corea 26
BR - Brasile 23
NL - Olanda 22
IR - Iran 21
DK - Danimarca 19
CZ - Repubblica Ceca 16
NG - Nigeria 12
SN - Senegal 12
CH - Svizzera 11
ES - Italia 11
PK - Pakistan 11
PT - Portogallo 11
TW - Taiwan 11
AU - Australia 10
JO - Giordania 8
RU - Federazione Russa 8
SA - Arabia Saudita 8
TR - Turchia 8
AR - Argentina 7
MY - Malesia 7
GR - Grecia 6
IQ - Iraq 6
MX - Messico 6
ZA - Sudafrica 6
BG - Bulgaria 5
BZ - Belize 5
HR - Croazia 5
HU - Ungheria 5
IL - Israele 5
NO - Norvegia 5
RS - Serbia 5
CI - Costa d'Avorio 4
CO - Colombia 4
PH - Filippine 4
SK - Slovacchia (Repubblica Slovacca) 4
TH - Thailandia 4
CY - Cipro 3
MA - Marocco 3
CL - Cile 2
EG - Egitto 2
EU - Europa 2
GE - Georgia 2
MK - Macedonia 2
RO - Romania 2
BD - Bangladesh 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
EE - Estonia 1
IM - Isola di Man 1
LT - Lituania 1
LV - Lettonia 1
NZ - Nuova Zelanda 1
TG - Togo 1
UZ - Uzbekistan 1
Totale 6.618
Salva come PNG Salva come JPEG
Città #
Chandler 457
Santa Clara 388
Singapore 309
Dublin 292
Turin 157
Nyköping 138
Torino 131
Los Angeles 112
Ann Arbor 102
Columbus 98
Beijing 96
Vienna 92
Ashburn 87
Medford 81
Jacksonville 71
Princeton 62
Woodbridge 58
Dearborn 55
Houston 54
Milan 53
Fairfield 50
Redwood City 50
Rome 43
Fremont 42
Wilmington 42
Jakarta 37
Villeurbanne 36
Dong Ket 33
Guangzhou 29
Seattle 26
Brussels 23
Cambridge 23
Ottawa 23
Shanghai 23
Helsinki 22
Pisa 22
Nanjing 19
New York 19
Québec 17
Washington 16
Boston 15
Munich 15
Boardman 14
Hangzhou 14
Copenhagen 13
Menlo Park 13
Toronto 13
Viterbo 13
Warsaw 13
Abuja 12
Central 12
Delhi 12
London 12
Naples 12
Paris 12
West Jordan 12
Hefei 11
Rivoli 11
Ahmedabad 10
Bari 10
Mumbai 10
Chengdu 9
Hong Kong 9
Lappeenranta 9
Amman 8
Bradford 8
Buffalo 8
Chennai 8
Gunzenhausen 8
Lisbon 8
Tai Wan 8
Frankfurt am Main 7
Hebei 7
Krakow 7
Leeds 7
Montreal 7
Novara 7
Riverside 7
Tokyo 7
Uppsala 7
Alessandria 6
Amsterdam 6
Cassano Magnago 6
Chicago 6
Epsom 6
Florence 6
Leinì 6
Piemonte 6
Reston 6
San Diego 6
Taipei 6
Tampa 6
Tianjin 6
Barcelona 5
Belize City 5
Birmingham 5
Catania 5
Dammam 5
Durban 5
Jinan 5
Totale 4.006
Salva come PNG Salva come JPEG
Nome #
PROCEEDINGS OF THE MERCK & ELSEVIER YOUNG CHEMISTSSYMPOSIUM 301
DHODH inhibitors and leukemia: an emergent interest for new myeloid differentiation agents 250
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors able to restore in vitro and in vivo myeloid differentiation 239
Substituted 4-hydroxy-1,2,3-triazoles: synthesis, characterization and first drug design applications through bioisosteric modulation and scaffold hopping approaches 172
Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds 164
Development of Potent Human Dihydroorotate Dehydrogenase Inhibitors Able to Induces Myeloid Differentiation 162
New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold 154
N-Acetyl-3-aminopyrazoles block the non canonical NF-kB cascade by selectively inhibiting NIK 129
Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies 126
New inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3) based on benzoisoxazole scaffold and their potential application in cancer 123
4-Hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide: a novel inhibitor of the canonical NF-κB cascade 120
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 119
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors 118
A differentiating and apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 115
TOWARD A BIOISOSTERIC ALKAEST – APPLICATION TO THE BIOISOSTERIC MODULATION OF IMD-0354 110
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold: SAR of the Biphenyl Moiety 107
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentatomic Heterocycles 106
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentaatomic Heterocycles 102
Towards a Bioisosteric Alkaest: application to the bioisosteric modulation of IMD-0354 100
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by combination of in-silico ligand/structural pharmacophore models and scaffold hopping bioisosteric approaches 99
Design of new human Dihydroorotate Dehydrogenase inhibitors: amide bioisosterism in MEDS433 optimization 97
New Hydroxybenzoazole Inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3): Disclosure of SAR Investigation to Target Prostate Cancer 95
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase inhibitors 93
Synthesis and Structural Characterization of Regio Substituted 4-Hydroxy-1H-1,2,3-triazols as Possible Tool in Bioisosteric Applications 84
Targeting myeloid differentiation using potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 84
Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication 84
Design and synthesis of a library of pyrazolo[1,5-a]pyridine fluorophores for developing new fluorescent probes 84
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors 82
Design, synthesis and co-crystallization of new Plasmodium falciparum dihydroorotate dehydrogenase inhibitors based on hydroxypyrazole scaffold 82
4-Hydroxy-1H-1,2,3-Triazol-5-yl moiety as bioisoster of carboxylic group. Synthesis and pharmacological ionotropic glutamate receptors characterization of Glu analogues 81
Targeting Human Onchocerciasis: Recent Advances Beyond Ivermectin 78
A differentiating and apoptotic therapy for acute myeloid leukaemia using potent human dihydroorotate dehydrogenase inhibitors. 78
SUBSTITUTED 4-HYDROXY-1H-1,2,3-TRIAZOLES: SYNTHESIS AND BIOISOSTERIC APPLICATIONS 75
A new pro-apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 74
Multiple-targeting ligands for AKR1C3 enzyme and androgen receptor to target prostate cancer 72
The synergism between DHODH inhibitors and dipyridamole leads to metabolic lethality in acute myeloid leukemia 71
Synthesis of [18F]Brequinar as PET Imaging probes for human dihydroorotate dehydrogenase 71
Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy 69
Improvement of in vivo pharmacokinetic profile of M433, a potent and innovative hDHODH inhibitor. 69
Regioselective N‐Alkylation of Ethyl 4‐Benzyloxy‐1,2,3‐triazolecarboxylate: A Useful Tool for the Synthesis of Carboxylic Acid Bioisosteres 66
The inhibition of human DHODH by M433 leads to differentiation and apoptosis in acute myeloid leukemia 63
Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with hydroxypyrazole core: new scaffolds against malaria disease 62
The new generation hdhodh inhibitor meds433 hinders the in vitro replication of sars-cov-2 and other human coronaviruses [Calistri A.*, Luganini A.*, co-first author] 62
Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia 58
Use of the 4-hydroxy-triazole moiety as a bioisosteric tool in the development of selective ligands for subtypes AMPA receptor 56
Apoptotic and differentiating therapy for AML using potent human dihydroorotate dehydrogenase inhibitor 56
Preliminary ADME/PK studies of new hDHODH inhibitors effective for treatment of acute myeloid leukaemia (AML) 55
Improvement of metabolic weakness of new human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold 55
Hydroxylated heterocycles as a bioisosteric tool to Modulate the carboxylic function into design potent human Dihydroorotate Dehydrogenase inhibitors 55
Develop of new fluorescent probe to target hDHODH enzyme 52
A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats 52
Design, synthesis and co-crystallization of new Plasmodium falciparum dihydroorotate dehydrogenase inhibitors based on hydroxypyrazole scaffold 51
Dihydroorotate dehydrogenase inhibitors in anti-infective drug research 50
Preliminary ADME/PK studies of new hDHODH inhibitors effective for treatment of acute myeloid leukaemia (AML) 50
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentatomic Heterocycles 50
Synthesis, physiochemical proprieties and application of hydroxyazole systems as carboxylic acid isoster 49
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia 49
Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic 48
Hydroxyazoles as acid isosteres and their drug design applications—Part 2: Bicyclic systems 48
Targeting myeloid leukemias using human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold: overcoming of metabolic issues 47
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Aryloxyaryl Moiety 45
Hydroxypyrazolol[1,5-a]pyridine as a fluorescent carboxylic acid isostere: development of new fluorescent 4-PHP analogues 45
Antileishmanial activity of some 4-phenyl-3-amino-1H-pyrazols designed as CRK3 kinase inhibitors 45
Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against respiratory syncytial virus replication 44
Synthesis of [18F] Brequinar as PET Imaging probes for human dihydroorotate dehydrogenase 44
Hydroxyazoles as acid isosteres and their drug design applications—Part 1: Monocyclic systems 44
New human dihydroorotate dehydrogenase inhibitors able to restore myeloid differentiation in AML 44
Improving the fluorescent profile of pyrazolo [1,5-a]pyridine fluorophores for developing new fluorescent probes 40
Important steps into drug development of MEDS433, a potent human dihydroorotate dehydrogenase inhibitor based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold 40
Toward a Bioisosteric Alkahest: Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentatomic Heterocycles 40
Targeting Myeloid Leukemias Using human Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: Overcoming of Metabolic Issues 38
HYDROXYLATED HETEROCYCLES AS BIOISOSTERES OF THE CARBOXYLIC FUNCTION: DESIGN OF NEW AKR1C3 INHIBITORS ACTIVE IN PROSTATE CANCER 37
Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2- hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic 37
Important Steps into Drug Development of MEDS433, a Potent Human Dihydroorotate Dehydrogenase Inhibitor based on the 2-hydroxypyrazolo[1,5-a] Pyridine Scaffold 36
Investigation of the central core of MEDS433: A Bioisosteric voyage into the Amide's Role. 34
A new generation of AKR1C3 inhibitors on the horizon: the 3- hydroxybenzazole approach to target prostate cancer 33
Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer 32
The Novel hDHODH Inhibitor MEDS433 Prevents Influenza Virus Replication by Blocking Pyrimidine Biosynthesis 31
Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias 31
Enhancement of the metabolic stability in 2-hydroxypyrazolo[1,5-a]pyridine scaffold-based inhibitors of human dihydroorotate dehydrogenase (hDHODH) 30
Synthesis of [18F]Brequinar as PET Imaging probes for human dihydroorotate dehydrogenase 27
Overcoming of metabolic issues in 2-hydroxypyrazolo[1,5-a]pyridine scaffold-based inhibitors of human dihydroorotate dehydrogenase: the story of MEDS700 27
Biochemical characterization of Mycobacterium tuberculosis dihydroorotate dehydrogenase and identification of a selective inhibitor 27
Turning the light on with pyrazolo[1,5-A]pyridine: exploring it’s fluorescent properties for the design of new fluorosteric compounds 24
The therapeutic potential of PIN-1 inhibition: new agents and strategic approaches 24
Use of the 4-Hydroxytriazole Moiety as a Bioisosteric Tool in the Development of Ionotropic Glutamate Receptor Ligands 24
Exploring Novel Compounds Targeting Mycobacterium tuberculosis Dihydroorotate Dehydrogenase: SAR Analysis and Biological Activity 22
Investigation of the central core of MEDS433: A Bioisosteric voyage into the Amide's Role 21
Optimization of MEDS433 synthesis: scale-up for preclinical evaluation studies 21
An alternative conformation of the N-terminal loop of human dihydroorotate dehydrogenase drives binding to a potent antiproliferative agent 20
NEW AKR1C3 INHIBITORS WITH BENZOISOXAZOLE CORE: DESIGN, SYNTHESIS AND BIOLOGICAL ACTIVITY TO TARGET PROSTATE CANCER 20
Targeting dihydroorotate dehydrogenase (DHODH) in anti-infective research: focusing in the design of on anti-malarial and anti-tuberculosis agents 19
Discovery of novel and potent human Dihydroorotate Dehydrogenase inhibitor that induces differentiation and apoptosis in Acute Myeloid Leukaemia 18
Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias 18
Identification of a potent and innovative inhibitor of human Dihydroorotate Dehydrogenase, triggering differentiation and apoptosis in Acute Myeloid Leukaemia 17
Scaling up synthesis and in vivo evaluation of MEDS433: a promising preclinical candidate targeting AML 17
Optimization of MEDS433 synthesis: scale-up for preclinical evaluation studies 16
Targeting Plasmodium falciparum dihydroorotate dehydrogenase: design, synthesis, co-crystallization and biological evaluation of new 3-hydroxypyrazole scaffold-based inhibitors 16
Targeting Plasmodium falciparum dihydroorotate dehydrogenase: design, synthesis, co-crystallization and biological evaluation of new 3-hydroxypyrazole scaffold-based inhibitors 16
Identification of Human Dihydroorotate Dehydrogenase Inhibitor by a Pharmacophore-Based Virtual Screening Study 15
Totale 6.752
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.743
article - articoli 0
book - libri 0
conference - conferenze 17.349
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.092
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020384 0 0 0 0 0 64 102 31 36 61 58 32
2020/2021505 55 55 34 30 40 15 32 16 69 48 39 72
2021/2022892 41 17 56 62 35 41 39 38 20 116 261 166
2022/20231.675 160 195 65 155 134 401 126 103 136 50 87 63
2023/20241.027 113 114 67 65 60 99 161 37 13 96 77 125
2024/20251.484 75 203 185 316 480 225 0 0 0 0 0 0
Totale 6.826